mo farah l carnitine Farah, Alberto Salazar and L-carnitine Q&A: everything we know BBC Panorama: Farah changed his

MiR-126-3p inhibits the proliferation of granulosa cells by inhibiting PDGFR and its downstream PI3K-AKT pathway, thus affecting the estrous cycle and hormone secretion in mice (Jiang et al., 2023)

And it gets worse

This dual pharmacology was achieved through iterative structure-activity relationship studies that balanced the competing requirements of GIP receptor affinity, GLP-1 receptor activation, and resistance to DPP-4 degradation

Its not just about the date printed on the vial

Risks and Unknowns Remaining research gaps include: Long-term systemic administration data Optimal dosing strategies outside dermatology Interaction with copper metabolism disorders Comparative efficacy versus standard wound treatments Most evidence supports local, tissue specific effects rather than systemic transformation

10.1016/j.pep.2005.09.021